Tag:

regenerative medicine

Latest Headlines

Latest Headlines

Wound care player Acelity lines up for what could be a $1B IPO

Private equity players took wound care company Kinetic Concepts private in a $5 billion buyout in 2011. Then these investors rolled in wound care peer Systagenix for $485 million in October 2013. Prior to that, KCI had already beefed itself up with the 2008 acquisition of tissue regeneration player LifeCell for $1.7 billion.

Regenerative med researchers advance work on recycling discarded kidneys

Can discarded kidneys--or replacement parts from pigs--be prepped for use later as transplants? A regenerative medicine team at Wake Forest Baptist Medical Center says they've successfully completed two preclinical steps in that direction, raising the possibility that they can deliver a new source of these organs.

Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact

Celgene has stepped up with a deal to buy a $45 million chunk of Mesoblast's stock at a premium price in exchange for a front row seat on the Australian biotech's stem cell pipeline and a preferred spot at the bargaining table if it follows up with a licensing deal.

Human stem cells can be 'reset' to their earliest state

European and Japanese scientists have figured out how to "reset" human pluripotent stem cells, turning back the clock on cells so that they revert to their original state at the height of their development potential.

J&J pours another $20M into ViaCyte and sizes up its diabetes treatment

Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.

Olympus is selling the OP-1 plant it bought from Stryker 4 years ago

In 2010, Olympus bought Stryker's troubled OP-1 putty for $60 million, hoping to expand its market. Now, the Japanese maker of medical devices and cameras says it's selling the Lebanon, NH, plant where the putty is made at a bargain price--and if it can't make a deal it will close the facility.

Wall Street cools to CryoLife's new guidance

Investors turned a cold shoulder to CryoLife Thursday after the Atlanta med tech and tissue processing company posted new guidance short of what Wall Street analysts had predicted.

Shire has a partially built plant for sale after unloading Dermagraft

Shire announced Friday it was selling the diabetic foot ulcer treatment to Canton, MA-based Organogenesis, which is not paying anything up front but could pay Shire up to $300 million if it meets sales targets up to 2018. With the deal, Organogenesis, which has its own foot ulcer product, gets the company's current 115,000-square-foot manufacturing plant in La Jolla, CA, but not the new facility.

Shire takes an L on Dermagraft, unloads it to Organogenesis

Shire's once-promising foray into regenerative medicine has largely been a bust, and now the Irish company is handing its costly Dermagraft program to Organogenesis in exchange for little but milestone payments.

Organogenesis slashes its R&D staff as Medicare preps a big price cut

The regenerative medicine company Organogenesis is slashing jobs as part of its company-wide reorganization in the face of Medicare's decision to cut what it's paying for its wound-healing medicine Apligraf.